CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 20221/S012

CHEMISTRY REVIEW(S)

CONTRACTOR DELICATION	1. ORGANIZATION	2. NDA NUMBER	1
CHEMIST'S REVIEW	HFD-150 DODP	20-221	
3. NAME AND ADDRESS OF APPLICANT (City and State)		4. AF NUMBER	
U.S. Bioscience, Inc.			
One Tower Bridge			
100 Front Street, Suite 400		5. SUPPLEMENT NUMBER / DATES	
West Conshochocken, PA 19428			
	L a MONDROPPIET ADVINANCE		T =====
6. NAME OF DRUG	7. NONPROPRIETARY NAME	SE ₁ -012	23-DEC-1998
Ethyol [®] for Injection	amifostine for injection		
8. SUPPLEMENT PROVIDES FOR:		9. AMENDMENTS DATES	
use of Ethyol to reduce the incidence and severity of radiation induced			
xerostomia. This review covers: (1) the	claim of Categorical Exclusion	ļ	
under 21 CFR 25.31(b) from the require		ļ	
Environmental Assessment and (2) appl		ļ	
10. PHARMACOLOGICAL CATEGORY	11. HOW DISPENSED	12. RELATED	IND/NDA/DMF
chemoprotective agent	RX xx OTC		
13. DOSAGE FORM(S)	14. POTENCY	1	
sterile lyophilized powder for injection	500 mg/vial	1	
15. CHEMICAL NAME AND STRUCTURE	1	16. RECORDS	AND REPORTS
2-[(3-aminopropyl)amino]ethanethiol dihydrogen phosphate (ester)		CURRENT YES_NO	
2-[(3-ammopi opyi)ammojetaaaetaisi a	inj di ogon prooprise (esses)	REVIEWED Y	ES_NO
HANCHANDICHAS DO H. MAN-	= 214.23 C ₅ H ₁₅ N ₂ O ₃ PS		
$H_2N(CH_2)_3NH(CH)_2S-PO_3H$ $MW = 214.23$ C_5H_{15} N_2O_3PS		ļ	•
			•
17. COMMENTS			
1			

Cc:

Orig. NDA 20-221 HFD-150/Div File HFD-150/RPBarron HFD-150/Mpelosi
HFD-150/Mpelosi
15 6-1-99

18. CONCLUSIONS AND RECOMMENDATIONS

Based on the amount of less than 1 ppb of the active moiety, amifostine, as the estimated concentration at the point of entry in the aquatic environment, the supplement qualifies for a categorical exclusion under CFR 25.31(b). The preparation of an environmental assessment or environmental impact statement is therefore not required. Approval of the supplement with regard to the environmental assessment requirements is recommended. Orphan designation was granted for this new indication in letter dated 12-MAY-1998 from the FDA Office of Orphan Products Development. The chemical name in the PI should revised to the univerted name.

.9. REVIEWER NAME	SIGNATURE	101	DATE COMPLETED		
Robert P. Barron		151	5/28/99		
DISTRIBUTION ORIGINAL JACKET XX	DIVISION FILE XX	REVIEWER XX CSO XX	SUP. CHEMIST XX		